Hubli
Sl. No | Principal Investigator’s Name | Study Title | Phase | Protocol ID | Indication | Study Status | Contact person & Phone Number |
---|---|---|---|---|---|---|---|
1 | Dr Vishal Kulkarni | A Multicenter, Double-Blind, Randomized, Parallel-Group, Active-Controlled, Two Part, Phase III, Global Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BP02 (Trastuzumab) in comparison wit+D15h Herceptin®-EU in Patients with HER2-Positive Early Breast Cancer (EBC) and HER2-Positive Metastatic Breast Cancer (MBC). | Phase 3 | CR-201-18 | HER2-Positive Metastatic Breast Cancer (MBC). | Ongoing with Recruitment | Prasad/9550939397 |
2 | Dr Vinaykumar Muttagi | A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy. | Phase 3 | 0063-17 | “triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.” | Ongoing with Recruitment | Manisha/9030545730 |
3 | Dr Vishal Kulkarni | Collection of blood and tissue samples from subjects diagnosed with Esophageal Cancer to evaluate biomarker expression profiles | NA | SLS – GNE – 01 | “Esophageal Adenocarcinoma & Esophageal Squamous Cell Carcinoma” | Ongoing with Recruitment | Meghana/7996393350 |
4 | Dr Vishal Kulkarni | Collection of blood samples from subjects diagnosed with Non-Small Cell Lung Carcinoma to evaluate biomarker expression profiles | NA | SLS – GNE – 02 | “Non-Small Cell Lung Carcinoma “ | Ongoing with Recruitment | Meghana/7996393350 |
5 | Dr Vishal Kulkarni | A Phase IIb/III, Randomised, Double-blind, Placebo-controlled, Multicentre, Study of CA-170 in Combination with Chemotherapy and Radiation in Patients with Unresectable Stage III or IVa Non-Squamous Non-Small Cell Lung Cancer (ASIAD-2) | Phase 2b/3 | CA-170-301 | “Stage III or IVa Non-Squamous Non-Small Cell Lung Cancer “ | Ongoing with Recruitment | Manjunath /9845764235 |